Low-density lipoprotein cholesterol (LDL-C) remains the primary target of lipidlowering therapy. Achieving LDL-C goals as outlined by the National Cholesterol Education Program Adult Treatment Panel III can be difficult with statins alone; therefore, adjunctive therapy is often indicated to reduce cardiovascular risk. Ezetimibe, a potent inhibitor of intestinal cholesterol absorption, has been shown to be safe, tolerable and effective at lowering LDL-C, non-high-density lipoprotein cholesterol and apolipoprotein B, each of which has been correlated with improved clinical outcomes, alone or in combination with a statin. However, because of randomized trials that demonstrated mixed results about atherosclerotic plaque regression via carotid intima-media thickness and a concern about cancer risk, ezetimibe 0 s role in lipid therapy has been questioned. Currently, a large randomized controlled trial is in progress to answer if ezetimibe improves clinical outcomes in patients with high-risk acute coronary syndrome. A smaller trial in patients with chronic kidney disease demonstrated reduced clinical events, including myocardial infarction, stroke and revascularization for patients taking the combination of ezetimibe and simvastatin versus those taking statin or placebo alone. In this paper, we review the trials that have led to the ezetimibe controversy and then discuss the possible role of ezetimibe in specific patient populations until the results of ongoing clinical trials are known.
Introduction
Low-density lipoprotein cholesterol (LDL-C) is well established as the primary target of lipidlowering therapy. Based on evidence demonstrating incremental benefits with aggressive LDL-C reduction, the target for LDL-C has progressively decreased over the years. In 2004, the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) updated its previous guidelines to recommend an LDL-C goal of less than 100 mg/dl in high-risk patients and an optional goal of less than 70 mg/dl for patients at very high risk for coronary events [Grundy et al. 2004] . Although the magnitude of LDL-C reduction correlates with the reduction in cardiovascular (CV) events, a significant number of high-risk patients on statin monotherapy fail to achieve their NCEP goals [Jukema et al. 2010; Sachdeva et al. 2009; Santos et al. 2009; Hermans et al. 2009; Kotseva et al. 2008; Pearson et al. 2000] . A major impeding factor is that high-risk patients frequently require a 50% or greater reduction in LDL-C, a magnitude of reduction only achievable with potent statins used at high doses. With the greatest effect of a statin occurring at the starting dose, doubling of dose generally achieves an incremental reduction in the baseline LDL-C of approximately 6%. For instance, two doublings of simvastatin from 20 mg to 40 mg to 80 mg typically achieves a reduction in the baseline LDL-C that is 12% greater than that achieved with a starting dose of 20 mg [Illingworth, 2000; Jones et al. 1998 ]. Furthermore, up to 1015% of patients experience muscular symptoms [Harper and Jacobson, 2007] , and many cannot tolerate a dose sufficient to reach their LDL-C goal [LaRosa et al. 2005] . Of 1447 very high-risk patients surveyed in NEPTUNE II (NCEP program evaluation project utilizing novel-e technology) only 17.8% achieved an LDL-C level less than 70 mg/dl [Davidson et al. 2005 ].
The challenge of attaining more aggressive LDL-C goals led to the discovery of ezetimibe, a drug with a mechanism of action complementary to that of statins. In combination therapy with statin, ezetimibe has been shown to reduce LDL-C by 4560%, with an overall safety profile similar to the respective monotherapies [Farnier et al. 2009 ]. Despite the benefits, the efficacy and safety of ezetimibe has been questioned and its place in lipid management strategies remains uncertain. We provide an in-depth review of the evidence from clinical trials and discuss the implications for ezetimibe use in clinical practice.
Pharmacology
Plasma cholesterol levels are regulated by feedback mechanisms that involve a reciprocal relationship between endogenous cholesterol synthesis and intestinal absorption of exogenous cholesterol. It is estimated that about 55% of ingested cholesterol is absorbed via the gastrointestinal tract, a value that has considerable genetic influence [Farmer, 2008] . Although the precise mechanism of cholesterol absorption is not known, the recently identified Niemann-Pick C1 Like 1 (NPC1L1) protein expressed at the jejunal brush border cells has been shown to play a crucial role [Altmann et al. 2004] . The primary action of statins is to inhibit hepatic cholesterol production by blocking HMG-CoA reductase, the rate-limiting enzyme essential for cholesterol synthesis [Toth et al. 2010] . It has been shown that statin induced downregulation of cholesterol synthesis is compensated for by a rise in intestinal cholesterol absorption [Lamon-Fava et al. 2007; Matthan et al. 2003; Miettinen and Gylling, 2003] . Although the exact mechanism is not known, recent data indicate that statins, particularly at high doses, stimulate the intestinal expression of NPC1L1 [Tremblay et al. 2011] . In contrast to statins, ezetimibe blocks NPC1L1 to inhibit the intestinal absorption of dietary and biliary cholesterol [Toth et al. 2010; Davis and Veltri, 2007; Garcia-Calvo et al. 2005] . These findings led to the concomitant use of ezetimibe and statin in an effort to achieve dual inhibition of the two major sources of serum cholesterol, hepatic and dietary. Combination statin plus ezetimibe therapy has been associated with significantly greater LDL-C reduction than that achieved with statin alone [Toth et al. 2010; Ballantyne et al. 2003; Kerzner et al. 2003; Melani et al. 2003 ]. While LDL-C is significantly reduced, it has been hypothesized that high-density lipoprotein cholesterol (HDL-C) transport is also downregulated [Kasza et al. 2009; Labonte et al. 2007 ].
The effectiveness of ezetimibe on LDL-C has been demonstrated in multiple trials. The EASE (Ezetimibe Add-On to Statin for Effectiveness) trial [Pearson et al. 2005 ], a randomized, double-blind, placebo-controlled study of 3030 patients, found that nearly threefold more patients assigned to ezetimibe plus statin achieved their target LDL-C than those on placebo plus statin (71% versus 20.6%, p < 0.001).
In the recently published IN-CROSS study [Farnier et al. 2009 ] high-risk patients who were not at their LDL-C goal on a stable dose of statin monotherapy were randomized to ezetimibe/simvastatin (10/20 mg) or rosuvastatin (10 mg) for 6 weeks. Treatment with ezetimibe/simvastatin provided an additional 11% reduction in statintreated baseline values of LDL-C compared with that achieved with rosuvastatin 10 mg ( p 0.001).The switch to ezetimibe/simvastatin resulted in clinically significant increases in the proportion of patients achieving LDL-C goals ( p 0.001). Interestingly, a significant treatment-by-stratum interaction ( p ¼ 0.013) was detected, with ezetimibe producing greater LDL-C reduction on a background of more potent versus less potent statin.
Clinical safety
Data from large trials have not shown clinically significant differences in adverse effects with ezetimibe (10 mg) used in combination with statins (1080 mg) compared with statin monotherapy [Robinson et al. 2009; Catapano et al. 2006; Pearson et al. 2005] . A meta-analysis of 18 randomized clinical trials (n ¼ 14,497) showed that the overall safety profile of ezetime plus statin was comparable to that of statin alone [Kashani et al. 2008] . There is no evidence that ezetimibe added to any dose of statin increases the risk of adverse effects, including myopathy or hepatic enzyme elevations.
In a study involving 1873 patients, an unexpected safety concern was raised in the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial [Rossebo et al. 2008] . The study reported an increase in any new onset cancer ( p ¼ 0.01), and cancer deaths ( p ¼ 0.05) in the ezetimibe plus simvastatin group compared with placebo. However, in a much larger independent metaanalysis involving 20,617 patients , preliminary safety data from the Improved Reduction of Outcomes: Vytorin Efficacy International (IMPROVE-IT), and the Study of Heart and Renal Protection (SHARP) trials showed no overall excess risk for cancer ( p ¼ 0.61). The US Food and Drug Administration, in a large postmarketing analysis of adverse effects filed for ezetimibe and ezetimibe/simvastatin, concluded that it is unlikely ezetimibe or ezetimibe plus simvastatin increases the risk of cancer or cancer-related deaths [Alsheikh-Ali and Karas, 2009 ]. Furthermore, this finding is contradictory to evidence that substantial lowering of LDL-C is not associated with increased rates of cancer. In the JUPITER trial [Ridker et al. 2008] , despite achieving LDL-C levels of 55 mg/dl (levels similar to the treatment arm of SEAS), cancer rates were not higher with rosuvastatin compared with placebo. A metaanalysis of data from randomized statin trials has shown that intensive lowering of LDL-C with statins is not associated with any significant effects on the rates of cancer during approximately 5 years of treatment and follow up [Baigent et al. 2010; Kearney et al. 2008 ].
The controversy
Does the addition of ezetimibe to statins result in less atherosclerosis progression and a reduction in CV events compared with statins alone?
The first challenge to the efficacy of ezetimibe came from the ENHANCE trial (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) ] that included 720 patients with heterozygous familial hypercholesterolemia who received simvastatin plus either ezetimibe or placebo (Table 1) . Ezetimibe added to simvastatin reduced LDL-C by an additional 17% without added benefit in atherosclerosis regression as measured by carotid intima-media thickness (CIMT).
These negative findings are in contrast to the results reported from the Stop Atherosclerosis in Native Diabetics Study (SANDS) Howard et al. 2008] . A substudy of the SANDS trial comparing CIMT changes among patients treated with aggressive therapy using statin monotherapy, aggressive therapy with statin plus ezetimibe, or standard statin monotherapy reported that, at 36 months, CIMT progressed in the standard group while regression occurred with aggressive therapy in both ezetimibe and nonezetimibe subgroups ( p < 0.001) ( Table 1 ). The findings suggest that, for a similar change in LDL-C, ezetimibe plus statin has a similar beneficial effect on CIMT as statin alone. Compared with ENHANCE the positive results for ezetimibe in the SANDS trial could be related to a substantially greater baseline CIMT (0.81 versus 0.69 mm) and longer length of study that allowed greater precision in detecting CIMT regression.
The most recent challenge to ezetimibe came from the ARBITER 6-HALTS trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies) [Taylor et al. 2009 ], which compared the effectiveness of extendedrelease niacin (ERN) with ezetimibe added to baseline statin. A significant reduction in the mean CIMT was observed in the niacin group from baseline to 14 months (0.0142±0.0041, p ¼ 0.001), while ezetimibe was associated with a nonsignificant reduction in CIMT (0.0007±0.0035, p ¼ 0.84). Although the trial was not powered to detect significant differences in clinical outcomes, fewer CV events were reported in the ERN cohort. The investigators suggested that raising HDL-C may have a greater impact on CIMT than further lowering of LDL-C. While raising HDL-C may lead to regression of atherosclerosis as measured by CIMT, aggressive lowering of LDL-C, even in the setting of below target HDL-C, has been shown to correlate with a reduced risk of a first cardiovascular event [Baigent et al. 2010; Ridker et al. 2010] .
Is CIMT an appropriate primary endpoint for precluding use of lipid lowering agents? CIMT is a very well-documented and useful tool for indentifying population risk of major CV events as well as identification of risk factors [Chambless et al. 2000 ]. In population studies, CIMT has been shown to detect changes in plaque size of 0.01 mm per year with inconsistent association regarding clinical outcomes [Goldberger et al. 2010 ]. Thus, it is generally agreed that the use of this surrogate marker provides inadequate evidence upon which to base a decision regarding the efficacy of a drug. The 'gold standard' continues to be the reduction of hard clinical CV events.
The conflicting results of the trials leading to the ezetimibe controversy may be explained by lack of power to detect a difference in CV events while looking at the primary endpoint of change in CIMT [Prati et al. 2008; Bots, 2006 ]. The reliability of CIMT in predicting CV events has limitations, particularly when the duration of treatment is only 2 years. Furthermore, pretreatment in the ENHANCE trial could have jeopardized the ability to achieve the primary endpoint as the mean baseline CIMT was 0.69 mm.
Correlation of change in CIMT and clinical events was recently reported in a meta-analysis of 41 trials which included more than 18,000 patients [Costanzo et al. 2010 ]. The meta-analysis included trials which reported clinical endpoints and measured CIMT at baseline and at end follow up. The authors concluded that there was no association between CIMT regression and coronary heart disease events (Tau 0.91, p ¼ 0.37), cerebrovascular events (Tau 0.32, p ¼ 0.75) and all-cause death (Tau 0.41, p ¼ 0.69). These findings were not influenced by baseline patient characteristics, including baseline CIMT or CV risk profile. As long-term statin therapy has been shown to stabilize plaque by depleting lipid content without changing plaque volume [Underhill et al. 2008; Zhao et al. 2001] , it is reasonable to conclude that the high prevalence of statin pretreatment and near normal CIMT at baseline in the ENHANCE trial prevented ezetimibe from inducing any change in atherosclerosis as measured by CIMT over the short follow up of 2 years.
Clinical outcomes trials
While controversy remains regarding CIMT plaque regression and its association with clinical events, the IMPROVE-IT trial ] trial examining patients with high-risk acute coronary syndrome will attempt to answer this question. The primary objective of this ongoing randomized, active-control, double-blind study is to evaluate the clinical benefit of ezetimibe/simvastatin 10/40 mg compared with simvastatin 40 mg in approximately 18,000 patients followed for a minimum of 2.5 years until at least 5250 patients experience a primary endpoint. Clinical benefit has been defined as the reduction in the composite endpoint of CV death, major coronary events, and stroke.
Results from this study are expected in 2013.
A similar trial in patients with chronic kidney disease recently reported their findings. The SHARP trial [Sharp Collaborative Group, 2010 ] evaluated nearly 9500 patients aged 40 or over with chronic kidney disease recruited from 380 hospitals in 18 countries. Patients with no known history of myocardial infarction or coronary revascularization were randomized in a ratio of 4:4:1 to ezetimibe 10 mg plus simvastatin 20 mg daily versus matching placebo versus simvastatin 20 mg daily (with rerandomization of the simvastatin only group at 1 year to ezetimibe 10 mg plus simvastatin 20 mg daily versus placebo) for an average of 5 years. The results were reported in November 2010, and concluded that the combination of ezetimibe and simvastatin lowered blood cholesterol levels and resulted in an approximate 25% reduction of myocardial infarction, cerebrovascular accidents, and coronary revascularization.
Implications for clinical practice
Because of their established efficacy and safety, statins remain the mainstay of lipid-lowering regimens for reducing CV events and improving survival in people with coronary disease and those at risk of disease. After lifestyle changes, the first priority should be titration to the maximally tolerated and effective dose of a statin. In addition to LDL-C reduction, statins have dose-dependent anti-inflammatory effects [Ridker et al. 2008; Deedwania et al. 2006 ] which may reduce CV events and atherosclerosis progression. The choice of statin for a particular patient depends on the degree of LDL-C reduction needed to achieve the desired goal, potency of the drug, cost, potential for drugdrug interactions, and drug availability.
Despite aggressive LDL-C reduction with statin therapy, there remains a high residual risk of coronary events. A meta-analysis of statin trials showed that the 5-year risk of a CV event in those receiving statins was 14% compared with 18% in those receiving placebo [Baigent et al. 2005 ]. This high residual risk of coronary events suggests that the treatment focus on LDL-C alone is not sufficient. An analysis of the Treating to New Targets (TNT) trial [Barter et al. 2007] showed that in patients with LDL-C below 70 mg/dl, those in the highest quintile of HDL-C levels were at a significantly lower risk for major CV events than those in the lowest HDL-C quintile ( p < 0.03). Meanwhile, low HDL-C and elevated triglycerides remain predictors of CV events in patients receiving aggressive statin therapy [Miller et al. 2008; Barter et al. 2007 ]. Therefore, consideration should also be given to treating HDL and non-HDL-C.
Once maximal therapeutic lifestyle changes have been achieved, patients who fail to meet their target LDL-C goals on statin therapy (either due to reaching the maximal statin dose or statin intolerance), or whose other lipid parameters are not at the required level, should be considered for combination therapy. The choices for therapies to supplement statins include niacin, fibrates, omega-3 fatty acids, bile acid sequestrants, and ezetimibe. Average impacts of various lipid-modifying agents on LDL-C, HDL-C, and triglycerides are listed in Table 2 . Elevated triglycerides and non-HDL-C can be lowered with niacin, omega-3 fatty acids, and fibrates. Treatment algorithms have recently been published [Rubenfire et al. 2010] . Present evidence supports the use of statins and niacin as the preferred combination for patients with mixed hyperlipidemia, particularly those with low HDL-C. However, compliance with niacin may be a problem due to adherence-limiting side effects, particularly flushing. The extendedrelease formulation appears to have less flushing and is better tolerated [Rubenfire, 2004] . Those with persistent elevation of non-HDL-C on statin plus niacin may be considered for the combination of statin plus omega-3 fatty acids. Addition of moderate-to high-dose (4000 mg) of omega-3 fatty acids to a statin is safe and effective for lowering LDL-C and triglycerides, but has minimal effect on HDL-C [Davidson et al. 2009 ]. Bile acid sequestrants are not recommended if triglycerides are greater than 300 mg/dl. Fibrates are primarily used for hypertriglyceridemia. The clinical CV benefit of fibrates, however, has been inconsistent and combination with a statin can lead to increased risk for myopathy [Usman and Peter, 2007] .
While questions remain about ezetimibe's effect on clinical outcomes, consideration should be given to treatment of specific subsets of patients, including those intolerant to statins, bile resins and niacin. Owing to the potential for fetal harm, all statins are considered category X and Table 2 . Average responses to lipid-lowering agents available in the USA.
Agent

LDL-C (%) HDL-C (%) TG (%)
High-potency statins Atorvastatin À30 to À60 + 7 to + 10 À25 to À46 Rosuvastatin À45 to À63 + 8 to + 14 À10 to À35 Pitavastatin À31 to À45 + 1 to + 8 À13 to À22 Moderate-potency statins Simvastatin À24 to À46 + 5 to + 21 À1 to À46 Low-potency statins Fluvastatin À19 to À32 + 3 to + 8 À0 to À11 Lovastatin À24 to À40 + 5 to + 19 À3 to À22 Pravastatin À18 to À35 + 4 to + 16 À1 to À25
Absorption inhibitors
Cholestyramine À11 to À31 + 3 to + 5 May increase Colesevelam À10 to À15 NC NC Colestipol À16 to À29 + 3 to + 5 May increase Ezetimibe À18 + 1 À8 Niacin
Immediate release À13 to À21 + 10 to + 24 À19 to À24 Extended release À13 + 19 À10 Fibrates
Gemfibrozil ±10 + 10 À43 Fenofibrates À17 to À35 + 2 to + 34 À32 to À53 Omega-3 fatty acids* + 10 + 0 to + 9 À25 to À50
Combination products
Ezetimibe/simvastatin À45 to À60 + 6 to + 10 À23 to À31 Extended release niacin/lovastatin À30 to À42 + 20 to + 30 À15 to À35 should not be used in women who are or may become pregnant. The use of statins is contraindicated in pregnancy and can be administered to women of childbearing age only when such patients are highly unlikely to conceive [Manson et al. 1996] . Well-controlled studies of ezetimibe in pregnancy are lacking.
High-risk patients (based on level of LDL-C or risk factors) and those with known atherosclerotic disease who fail to reach LDL-C levels reasonably close to targets (e.g. within 10%) could benefit from the addition of ezetimibe. Among the lipid-lowering drug therapies, ezetimibe would be the most tolerable. In addition to lowering the total and LDL-C, ezetimibe reduces apolipoprotein B (apo B), non-HDL-C, triglycerides, and the ratios total C/HDL-C and apo B/ apoA-1. Patients with elevated LDL-C or combined elevated cholesterol and triglycerides who are statin intolerant may be considered for ezetimibe in combination with high-dose marine oil, bile resins, and fibrates.
Conclusion
While the efficacy of ezetimibe in combination with statin therapy has shown greater LDL-lowering effects compared with statin alone, whether these effects will translate into a reduction in CV events awaits the results of ongoing CV outcome trials. Until such data are available, the use of ezetimibe in lipid management therapies warrants careful consideration.
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